Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the Netherlands / NCT06122363
Active, not recruiting Observational

Impact of Incomplete Endometrial Ablation

NCT06122363 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Maxima Medical Center
Phase
Observational
Started
2023-03-01
Last updated
2025-06-12

Condition(s) studied

Heavy Menstrual Bleeding

Investigational drug(s) / intervention(s)

hysteroscopy

hysteroscopy: uterine hysteroscopy right after Novasure endometrial ablation

Study summary

The aim of the proposed protocol is to study the impact of incomplete endometrial ablation on the PBAC score, reintervention, satisfaction, controlled bleeding and dysmenorrhea at 24 months after Novasure endometrial ablation, in women with heavy menstrual bleeding treated at Máxima Medical Centre Veldhoven, in The Netherlands.

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Endometrial ablation between 2012 and 2023 in Máxima Medical Centre * Women had to suffer from heavy menstrual bleeding Exclusion Criteria: \- No saved hysteroscopy images or bad quality hysteroscopy images

Primary outcome measure(s)

  • Pictorial Blood Assessment Chart (PBAC) score — 24 months
    Blood loss of 1 month, measured by the number of needed tampons/pads and how heavily they are filled with blood. The higher the score, the more severe blood loss. From 150 points the amount is defined as heavy menstrual bleeding.

Trial sites (1)

FacilityCityRegionStatus
Máxima MC Veldhoven North Brabant

More Maxima Medical Center trials in the Netherlands

A Twelve-Week Pilot Study Evaluating the Usability and Preliminary Effects of SugarVita 2.0 in Adults With Type 2 Diabetes Recruiting
Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice Recruiting
The Use of the Bambi-Belt in Exteremly Preterm Infants: an Implementation Study. Recruiting
Ketogenic Diet Prior to Bariatric Surgery Recruiting
Feasibility of Remote eCTG Monitoring Home@Hospital in Complicated Pregnancies Recruiting

Other trials for the same condition

Menstrual Complaints in Adolescents and Adults Active, not recruiting
Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06122363 on ClinicalTrials.gov ↗ ← All trials in the Netherlands